Straightforward and Highly Efficient Strategy for Hepatocellular Carcinoma Glycoprotein Biomarker Discovery Using a Nonglycopeptide-Based Mass Spectrometry Pipeline
datasetposted on 2019-09-09, 19:04 authored by Wei-Qian Cao, Bi-Yun Jiang, Jiang-Ming Huang, Lei Zhang, Ming-Qi Liu, Jun Yao, Meng-Xi Wu, Li-Juan Zhang, Si-Yuan Kong, Yi Wang, Peng-Yuan Yang
Efficient detection of aberrant glycoproteins in serum is particularly important for biomarker discovery. However, direct quantitation of glycoproteins in serum remains technically challenging because of the extraordinary complexity of the serum proteome. In the current work, we proposed a straightforward and highly efficient strategy by using the nonglycopeptides releasing from the specifically enriched glycoproteins for targeted glycoprotein quantification. With this so-called nonglycopeptide-based mass spectrometry (NGP-MS) strategy, a powerful and nondiscriminatory pipeline for hepatocellular carcinoma (HCC) glycoprotein biomarker discovery, verification, and validation has been developed. First, a data set of 234 NGPs was strictly established for multiple-reaction monitoring (MRM) quantification in serum. Second, the NGPs enriched from 20 HCC serum mixtures and 20 normal serum mixtures were labeled with mTRAQ reagents (Δ0 and Δ8, respectively) to find the differentially expressed glycoproteins in HCC. A total of 97 glycoprotein candidates were preliminarily screened and submitted for absolute quantitation with NGP-based stable-isotope-labeled (SID)-MRM in the individual samples of 38 HCC serum and 24 normal controls. Finally, 21 glycoproteins were absolutely quantified with high quality. The diagnostic sensitivity results showed that three glycoproteins, β-2-glycoprotein 1 (APOH), α-1-acid glycoprotein 2 (ORM2), and complement C3 (C3), could be used for the discrimination between HCC patients and healthy people. A novel glycoprotein biomarker panel [APOH, ORM2, C3, and α-fetoprotein (AFP)] has proven to outperform AFP, the known HCC serum biomarker, alone, in this study. We believe that this strategy and the panel of glycoproteins might hold great clinical value for HCC detection in the future.
Hepatocellular Carcinoma Glycoprotein Biomarker Discoverynovel glycoprotein biomarker panelα- fetoproteinSIDbiomarker discoveryserum proteomeNGP-based stable-isotope-labeledHCC serum biomarkerglycoprotein biomarker discoveryserum mixturesHCC detection97 glycoprotein candidates234 NGPscomplement C 3APOHsensitivity results21 glycoproteinsAFPNGP-MSNonglycopeptide-Based Mass Spectrometry Pipeline Efficient detection38 HCC serum20 HCC serum mixturesβ-2- glycoprotein 1hepatocellular carcinomaEfficient StrategyORMHCC patientsglycoprotein quantificationmultiple-reaction monitoringMRMnonglycopeptide-based mass spectrometry